Study #2023-0918
Low-dose Sirolimus to increase hematopoietic function in patients with RUNX1 familial platelet disorder.
MD Anderson Study Status
Enrolling
Treatment Agent
Sirolimus
Description
To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Familial Platelet Disorder, Hematopoietic
Study phase:
Phase II
Physician name:
Courtney DiNardo
Department:
Leukemia
For general questions about clinical trials:
1-844-929-4217
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.